10-Q: Arcellx Q3 2025: Losses Widen Amid R&D Spend, Cash Runway to 2028

Arcellx reported significantly increased net losses for Q3 and 9M 2025, driven by higher operating expenses and reduced collaboration revenue, while maintaining a cash runway into 2028.

Summary

• Net loss for the three months ended September 30, 2025, was $55.8 million, compared to $25.9 million for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, was $170.8 million, compared to $60.3 million for the same period in 2024.
• Collaboration revenue decreased significantly to $4.9 million for Q3 2025 from $26.0 million for Q3 2024, and to $20.6 million for 9M 2025 from $92.7 million for 9M 2024, primarily due to the completion of dosing and manufacturing for the iMMagine-1 trial in Q4 2024.
• Research and development expenses decreased by $4.1 million for Q3 2025 but increased by $11.1 million for 9M 2025, driven by higher internal costs, including $8.8 million in non-cash share-based compensation for the nine-month period.
• General and administrative expenses increased by $11.2 million for Q3 2025 and $21.9 million for 9M 2025, primarily due to commercial readiness costs and personnel-related expenses, including share-based compensation.
• Cash, cash equivalents, and marketable securities totaled $576.0 million as of September 30, 2025, which management believes is sufficient to fund operations into 2028.
• The company sold 1,905,715 shares of common stock in at-the-market offerings for net proceeds of $131.6 million during the nine months ended September 30, 2025.
• Preliminary data from the pivotal Phase 2 iMMagine-1 clinical trial for anito-cel in rrMM was presented at the 2025 European Hematology Association Congress (EHA 2025 Congress) in June 2025.
• Kite initiated a global Phase 3 randomized controlled clinical trial (iMMagine-3) of anito-cel in patients with second through fourth line rrMM in 2024, with Kite manufacturing anito-cel for this trial following FDA clearance of technical transfer in May 2024.
• FDA clearance of an IND application for ACLX-004, targeting CD33 and CD123 in relapsed or refractory AML, was recently received.
• A Phase 1 trial for anito-cel in generalized myasthenia gravis (gMG) was initiated in 2024.

Sentiment

Score: 4

Explanation: While the company has a strong cash runway into 2028 and continues to advance its pipeline with positive clinical and regulatory milestones (e.g., iMMagine-3 initiation, ACLX-004 IND clearance, gMG trial initiation, REMS elimination), the significant increase in net losses and cash burn, coupled with a sharp decline in collaboration revenue, indicates a worsening financial performance in the short term. The reliance on future funding and the competitive landscape also contribute to a cautious outlook.

Positives

• Cash, cash equivalents, and marketable securities of $576.0 million are believed to be adequate to fund operations into 2028, providing a solid financial runway.
• Successful completion of dosing in the pivotal Phase 2 iMMagine-1 trial for anito-cel in rrMM in 2024.
• Presentation of preliminary data from the iMMagine-1 trial at the 2025 EHA Congress in June 2025.
• Kite initiated a global Phase 3 trial (iMMagine-3) for anito-cel in earlier lines of rrMM in 2024, demonstrating continued partnership progress and commitment.
• Technical transfer of anito-cel manufacturing to Kite was completed and cleared by the FDA in May 2024, streamlining future production.
• FDA clearance of an IND application for ACLX-004, expanding the ARC-SparX pipeline.
• Initiation of a Phase 1 trial for anito-cel in generalized myasthenia gravis (gMG) in 2024, diversifying the pipeline into autoimmune disorders.
• Successful "at-the-market" offering program raised $131.6 million in net proceeds during the nine months ended September 30, 2025.
• FDA eliminated the Risk Evaluation and Mitigation Strategies (REMS) for currently approved BCMAand CD19-directed autologous CAR T cell immunotherapies in June 2025, which is expected to improve access to these approved therapies.

Negatives

• Net loss for Q3 2025 increased to $55.8 million from $25.9 million in Q3 2024, representing a significant worsening of profitability.
• Net loss for 9M 2025 increased to $170.8 million from $60.3 million in 9M 2024, indicating a substantial increase in losses year-over-year.
• Collaboration revenue decreased substantially to $4.9 million for Q3 2025 (from $26.0 million in Q3 2024) and to $20.6 million for 9M 2025 (from $92.7 million in 9M 2024), primarily due to the completion of iMMagine-1 trial activities.
• Operating expenses increased overall for the nine-month period, driven by higher general and administrative costs and internal R&D costs, contributing to wider losses.
• Interest income decreased due to lower overall cash and marketable securities balances.
• Accumulated deficit grew to $667.7 million as of September 30, 2025, reflecting continued significant operating losses.
• Net cash used in operating activities for 9M 2025 increased substantially to $152.1 million from $37.4 million in 9M 2024.
• Two directors adopted 10b5-1 trading plans to sell a combined 56,000 shares of common stock between December 2025 and December 2026.

Risks

• Limited operating history and significant accumulated losses make future viability difficult to assess.
• Need for substantial additional funding; inability to raise capital on acceptable terms could force delays or elimination of R&D programs or commercialization efforts.
• No products approved for commercial sale, with only one product candidate (anito-cel) in late-stage clinical development.
• ddCAR and ARC-SparX platforms are novel and unproven approaches, making development timing, results, and costs unpredictable, with potential difficulty in identifying appropriate target binding domains.
• ARC-SparX platform is highly dependent on the success of ACLX-001, ACLX-002, and ACLX-004.
• Clinical development is lengthy, expensive, and uncertain; clinical trials may fail to demonstrate adequate safety and/or efficacy.
• Potential for substantial delays in clinical trials, including difficulties enrolling patients.
• Product candidates may cause undesirable side effects (e.g., cytokine release syndrome, neurologic toxicities, T cell malignancies) or have other properties that could halt development, prevent approval, limit commercial potential, or result in negative consequences.
• Interim, preliminary, or topline data from clinical trials may change as more patient data become available and are subject to audit and verification.
• Manufacturing genetically engineered products is complex and subject to human and systemic risks, production/sourcing difficulties, and supply constraints of key components.
• Material modifications in manufacturing methods may result in additional costs or delays.
• Reliance on third-party manufacturers for clinical product supplies and candidates, with risks if they fail to provide sufficient quantities or acceptable quality.
• Dependence on Kite Pharma, Inc. for certain development, manufacturing, and commercialization activities; collaboration may not be successful.
• Inability to obtain and maintain sufficient intellectual property protection for platforms and product candidates, or if the scope is not broad enough, competitors could commercialize similar products.
• Third-party claims of intellectual property infringement may prevent or delay product discovery and development.
• Inability to obtain regulatory approval for product candidates; denial or delay would harm revenue potential.
• Increasing regulation as product candidates advance through clinical trials and commercialization.
• Even if approved, products may not gain market acceptance among physicians, patients, hospitals, cancer treatment centers, and others in the medical community.
• Impact of recent healthcare reform legislation (e.g., Inflation Reduction Act, OBBBA) and other changes in the healthcare industry on business model and profitability.
• Global economic, political, and market conditions (e.g., U.S. credit rating downgrades, inflation, geopolitical conflicts like Russia/Ukraine and Middle East) may adversely affect business.
• Adverse developments affecting the financial services industry (e.g., bank failures like SVB) could impair access to funding.
• High dependence on key personnel; difficulty attracting and retaining qualified personnel.
• Expected organizational growth may lead to management difficulties.
• Exposure to costly and damaging product liability claims, with insurance potentially inadequate.
• Internal computer systems and networks, or those of third parties, may fail or suffer security breaches.
• Employees, contractors, and partners may engage in misconduct or noncompliance with regulatory standards.
• Potential for lawsuits challenging inventorship or ownership of patents and intellectual property.
• Inability to protect the confidentiality of trade secrets.
• Inadequate protection of trademarks and trade names.
• Volatility of common stock price, adversely impacted by future events.
• Future sales and issuances of common stock, including by Gilead, could result in additional dilution and stock price decline.
• Do not intend to pay dividends on common stock.
• Charter documents and Delaware law provisions could delay or prevent a change of control.
• Exclusive forum provisions in bylaws could limit stockholders' ability to obtain a favorable judicial forum.
• Risk of securities class action litigation.

Future Outlook

The company expects to continue incurring significant expenses and increasing operating losses for the foreseeable future, with net losses fluctuating based on the timing and expenditures of research and development and commercial readiness activities. Operating expenses and capital requirements are expected to increase substantially as the company advances anito-cel, pursues regulatory approval, establishes commercial infrastructure, expands its pipeline, and protects intellectual property. Management believes current cash, cash equivalents, and marketable securities are adequate to fund operations into 2028, but substantial additional funding may be required. The company's ability to generate product revenue depends on successful development, regulatory approval, and commercialization of product candidates.

Management Comments

• "We believe cell therapies are one of the forward pillars of medicine, and our mission is to advance humanity by engineering cell therapies that are safer, more effective and more broadly accessible."
• "We believe we can address these limitations by engineering a new class of D-Domain powered cell therapies, including classical single infusion CAR-Ts called ddCARs and dosable and controllable universal CAR-Ts called ARC-SparX, to address hematologic cancers, solid tumors, and indications outside of oncology, such as autoimmune diseases."
• "We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future, and our net losses may fluctuate significantly from period to period, depending on the timing of and expenditures on our planned research and development activities and commercial readiness activities."
• "Based on our expected operating cash requirements and capital expenditures, we believe our current cash and cash equivalents and investments in marketable securities are adequate to fund operations into 2028."

Industry Context

Arcellx operates in the highly competitive and rapidly innovating biopharmaceutical industry, specifically within the cell therapy and immunotherapy space. The company's focus on novel D-Domain, ddCAR, and ARC-SparX platforms aims to overcome limitations of traditional CAR-T therapies, such as manufacturing difficulties, limited patient segments, high toxicity, and narrow applicability. The industry is seeing increased regulatory scrutiny, as evidenced by past FDA actions on CAR-T therapies (e.g., T cell malignancies boxed warning, though now reconsidering, and REMS elimination for approved products), which can impact development timelines and market acceptance. The company's collaboration with Kite Pharma (a Gilead company) for anito-cel development and commercialization is a significant strategic move in an industry where partnerships are crucial for sharing costs and leveraging expertise. The expansion into autoimmune disorders with anito-cel reflects a broader industry trend of exploring cell therapies beyond oncology. The general economic environment, including inflation and interest rate changes, also poses challenges for capital-intensive biotech companies.

Comparison to Industry Standards

• The company's lead program, anito-cel, is a BCMA-targeting ddCAR, competing in the relapsed or refractory multiple myeloma (rrMM) space. This is a highly competitive area with established players and numerous companies developing CAR-T or other genetically modified cell therapies, including 2seventy bio, Abbvie, Allogene, Amgen, AstraZeneca, Autolus, Bristol Myers Squibb, Caribou Biosciences, CARsgen, Cartesian, Cellectis, Cellular Biomedicine Group, Celyad, Crispr, Gilead, Gracell, GSK, Immix, Innovent, Johnson & Johnson, Legend, Nanjing IASO Biotherapeutics Ltd., Novartis, Pfizer, Poseida Therapeutics, Precision BioSciences, Pregene, Regeneron, and Roche.
• The company's ARC-SparX platform, including ACLX-002 targeting CD123 in AML/MDS, also faces competition from other immune cell therapies, bispecifics, and allogeneic cell therapies.
• The reported net losses and increased cash burn are typical for clinical-stage biopharmaceutical companies heavily invested in R&D, but the magnitude of the increase in net loss and cash used in operations for 9M 2025 compared to 9M 2024 is notable and indicates accelerated spending relative to revenue.
• The cash runway into 2028, supported by recent at-the-market offerings, is a positive indicator of liquidity compared to many early-stage biotechs that often have shorter runways.
• The FDA's elimination of REMS for approved BCMAand CD19-directed CAR T cell immunotherapies in June 2025 is a positive industry-wide development that could improve access and reduce commercialization burdens for future approved CAR-T therapies, including potentially anito-cel.

Corporate Governance

Legal Proceedings

• The company was not involved in any material legal proceedings as of September 30, 2025, and December 31, 2024.

Related Party Transactions

• Gilead Sciences, Inc. held approximately 12% of the company's outstanding common stock as of September 30, 2025.
• The company has a contract liability of $112.2 million to Kite Pharma, Inc. (a Gilead company) under the Collaboration and License Agreement as of September 30, 2025.
• Collaboration revenue from Kite Pharma, Inc. was $4.9 million for Q3 2025 and $20.6 million for 9M 2025.
• Kite Pharma, Inc. is responsible for manufacturing anito-cel for the iMMagine-3 trial.

Stakeholder Impact

• Shareholders: Experience increased net losses and dilution from recent at-the-market offerings. The stock price may be volatile due to financial performance and market conditions. The lapse of Gilead's transfer prohibition and potential future sales could impact share price.
• Employees: Increased personnel-related costs and share-based compensation indicate continued investment in the workforce. However, the company's need for additional funding and potential delays in product development could impact job security or future growth opportunities.
• Customers (future patients): Progress in clinical trials for anito-cel (iMMagine-1 data, iMMagine-3 initiation) and pipeline expansion (ACLX-004 IND, gMG trial) offer potential new treatment options for cancer and autoimmune diseases.
• Suppliers/Vendors: Continued reliance on third-party CROs and CMOs for R&D and manufacturing, but potential for supply chain disruptions and changes in manufacturing processes pose risks.
• Creditors: The company's substantial cash reserves and runway into 2028 provide a degree of financial stability, but increasing operating losses and the need for future funding could be a concern.

Next Steps

• Advance the clinical program for anito-cel and subsequent clinical trials focused on earlier lines of therapy in collaboration with Kite.
• Pursue regulatory approval of product candidates that successfully complete clinical trials.
• Establish a sales, marketing, and distribution infrastructure to commercialize any approved product candidates.
• Attract, hire, and retain additional clinical, scientific, manufacturing, management, administrative, and commercial personnel.
• Add operational, financial, and management information systems and personnel.
• Determine and execute the long-term manufacturing strategy for anito-cel in collaboration with Kite.
• Grow supply and contract manufacturing infrastructure.
• Initiate clinical trials to evaluate anito-cel in other indications outside of oncology.
• Initiate or continue to advance clinical trials for ACLX-001, ACLX-002, and other preclinical pipeline programs such as ACLX-004.
• Expand the pipeline of product candidates through discovery, acquisition, or in-licensing.
• Continue to develop proprietary platforms.
• Obtain, maintain, expand, and protect the intellectual property portfolio.
• Evaluate the impact of ASU No. 2023-09 "Improvements to Income Tax Disclosures" for adoption in 2025 annual consolidated financial statements.
• Evaluate the impact of ASU No. 2024-03 "Disaggregation of Income Statement Expenses (DISE)" for adoption in 2027 annual consolidated financial statements.

Key Dates

Recommendation

The company is a clinical-stage biopharmaceutical firm with a promising pipeline in cell therapy, including a lead candidate (anito-cel) in late-stage trials and a strong collaboration with Kite Pharma. The cash runway into 2028 provides significant operational flexibility. However, the substantial increase in net losses and cash burn, coupled with a sharp decline in collaboration revenue, indicates a challenging financial period. While clinical progress is positive, the inherent risks of drug development, intense competition, and the need for future funding warrant a cautious approach. A "hold" recommendation reflects the balance between the long-term potential of its innovative platforms and the near-term financial headwinds and execution risks. Investors should monitor clinical trial results, regulatory approvals, and future financing activities closely.

Keywords

Cell therapy, CAR-T, Multiple myeloma, AML, MDS, Autoimmune disorders, Anito-cel, ACLX-001, ACLX-002, ACLX-004, D-Domain, ARC-SparX, Kite Pharma, Gilead Sciences, Biopharmaceutical, Clinical trials, Oncology, Immunotherapy, SEC filing, 10-Q, Financial results, Biotechnology, Drug development, Clinical-stage, Relapsed refractory multiple myeloma, Acute myeloid leukemia, Myelodysplastic syndrome, Generalized myasthenia gravis, Regulatory approval, FDA, Intellectual property, Cash runway, Operating loss, Research and development, Commercialization